Jim Cramer on Stryker Corporation (SYK): “I Don’t Like It Enough”

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other stocks that Jim Cramer discusses.

When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied:

“I like Stryker, but you know, I don’t like it enough. I don’t like it as much as if it was Intuitive Surgical. That’s the one that I thought we should buy. ISRG.”

A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems.

Stryker (NYSE:SYK) is a medical technology company that supplies products like joint implants, spinal systems, surgical tools, patient safety equipment, neurosurgical devices, and other healthcare technologies. Toward the end of March, talking about the company, Cramer stated:

“Stryker is a good company and I think that a medical device company in this environment will do well. Now, there’s some people that are gonna say, listen, they’re going to be tariffs on that company. I’m not sure whether they’ll really matter. I think Stryker works in an environment where we’re putting 25% tariffs on all foreign cars. As I’ve been saying to you, Germany, Japan and Korea have to pay. I’ve been saying it and saying and saying it and it happened tonight. And people say, why didn’t we know? I don’t know what else I could do.”

Overall, SYK ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SYK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.